Ciprofloxacin-functionalized silver nanocomposite: a promising strategy against colistin-resistant Pseudomonas aeruginosa
Letters in Applied Microbiology · 06.04.2026 · 79 (4)
DOI: 10.1093/lambio/ovag027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied Microbiology, online erschienen am 07.04.2026. Verfasst von Sameera Mujahid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial Resistance Lab, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Ciprofloxacin, Pseudomonas aeruginosa, Silver, Nanocomposites. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Department of Biotechnology.
Abstract (Originalsprache)
The rapid rise of colistin resistance in Pseudomonas aeruginosa presents a critical challenge, necessitating innovative therapeutic alternatives. In this study, we developed a novel ciprofloxacin-functionalized silver nanocomposite (NC) by modifying phospholipid–PEG (polyethylene glycol)-coated silver nanoparticles to enhance antibacterial efficacy against colistin-resistant P. aeruginosa. The NC was comprehensively characterized by UV-Visible spectroscopy, dynamic light scattering, Fourier transform infrared spectroscopy, transmission electron microscope, scanning electron microscopy, and EDX, confirming spherical morphology with an average size of 29.74 nm. Biological evaluations revealed potent antibacterial and antibiofilm activity: CFU (colony forming unit) and crystal violet assays demonstrated a 6.9 log₁₀ CFU mL−1 reduction in bacterial colonies and a 31.45% decrease in biofilm formation. Mechanistic studies revealed an elevated production of reactive oxygen species, singlet oxygen, and hydroxyl radicals upon treatment, correlating with a 39.70% decline in bacterial viability in XTT assays. Importantly, methyl thiazolyl tetrazolium cytotoxicity tests against MLE12 cells confirmed the NC’s biocompatibility. Efficacy was further validated in an in vivo lung infection model in albino Wistar rats, where histopathological analysis and cytokine profiling confirmed therapeutic potential. Collectively, these findings establish ciprofloxacin-modified silver NCs as a stable, safe, and highly effective strategy for treating multidrug-resistant P. aeruginosa, offering a promising alternative to colistin in combating life-threatening lung infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antimicrobial Resistance Lab, Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India.
- Ramalingaswami Fellow, Multidisciplinary Centre for Advanced Research and Studies (MCARS), Jamia Millia Islamia, New Delhi 110025, India.
- Pathology Department, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh 202002, Uttar Pradesh, India.
ORCID-Profile: Asad U Khan
Förderung
- Department of Biotechnology
Zitieren
APA
Mujahid, S., Farooq, S., Talat, A., Iqbal, J., Akhtar, K., & Khan, A. U. (2026). Ciprofloxacin-functionalized silver nanocomposite: a promising strategy against colistin-resistant Pseudomonas aeruginosa. Letters in Applied Microbiology, 79(4). https://doi.org/10.1093/lambio/ovag027
Vancouver
Mujahid S, Farooq S, Talat A, Iqbal J, Akhtar K, Khan AU. Ciprofloxacin-functionalized silver nanocomposite: a promising strategy against colistin-resistant Pseudomonas aeruginosa. Letters in Applied Microbiology. 2026;79(4). doi:10.1093/lambio/ovag027
BibTeX
@article{Mujahid2026,
author = {Mujahid, Sameera and Farooq, Samiya and Talat, Absar and Iqbal, Jawed and Akhtar, Kafil and Khan, Asad U},
title = {Ciprofloxacin-functionalized silver nanocomposite: a promising strategy against colistin-resistant Pseudomonas aeruginosa},
journal = {Letters in Applied Microbiology},
year = {2026},
volume = {79},
number = {4},
doi = {10.1093/lambio/ovag027}
}
EUVIMED